Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07471789) titled 'Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL)' on March 10.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Gyala Therapeutics
Condition:
Acute Myeloblastic Leukaemia
Leukemia, T-Cell
Intervention:
Drug: CART84
Recruitment Status: Recruiting
Phase: Phase 1/Phase 2
Date of First Enrollment: February 4, 2026
Target Sample Size: 33
Countries of Recruitment:
Spain
To know more, ...